Hyperglycemia and outcome in intracerebral hemorrhage: from bedside to bench-more study is needed

Wuwei Feng1, Shunaiber Tauhid, Sweta Goel

  • 1Department of Neuroscience, MUSC Stroke Center, Medical University of South Carolina, Charleston, SC, USA.

Hyperglycemia on admission has been associated with poor outcome after intracerebral hemorrhage (ICH). However, the mechanistic links between hyperglycemia and poor outcome are not fully elucidated. We sought to determine the relationship between the serum glucose levels during the first 72 h after ICH, and evolution of hematoma and perihematomal edema (PHE), and functional outcome at 3 months and performed a retrospective review of prospectively collected data from 135 consecutive ICH patients. Patients were divided into two groups based on their mean glucose level-high (≥150 mg/dl) vs. controlled (<150 mg/dl). We used Chi-square test and multiple logistic regressions to assess the relationship between glucose level and outcome variables, including hematoma expansion (HE), PHE growth, and modified Rankin Scale (mRS) score at 3 months. The mean 72-h glucose level was 123 ± 16 for the controlled group and 190 ± 48 mg/dl for the high-glucose group. The corresponding rates of HE were 23.4 vs. 25.9 % (unadjusted p = 0.80; adjusted p = 0.08); PHE growth, 31.3 vs. 29.6 % (unadjusted p = 0.88; adjusted p = 0.39); and poor outcome at 3 months, defined as mRS score of ≥3, was 54 vs. 71 % (unadjusted p = 0.06; adjusted p = 0.89). On multivariate analyses, the ICH score emerged as the major predictor for poor outcome, but not glucose. In conclusion, we found a trend for an association between mean 72 h glucose levels and poor outcome at 3 months, but this effect attenuated after adjusting for the ICH score. High glucose was not associated with HE or PHE growth. More preclinical and clinical studies are needed to elucidate the role of hyperglycemia in ICH before embarking on large and costly clinical trials of tight glucose control in ICH patients.

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30